Pharma Commercialization Experts to Converge at Access Insights Conference 2023
The conference will focus on the full breadth of commercialization strategies and operations.
IntegriChain, a data and business process platform for the pharmaceutical industry, announced the final agenda for next month’s Access Insights Conference 2023, co-hosted with Blue Fin Group. The event will be held Nov. 6-8, 2023, at the JW Marriott Orlando Bonnet Creek. Designed for commercial, operational, and financial teams at pharma manufacturers, the conference will feature industry speakers, exclusive ICyte Benchmark data, and strategic and tactical best practices for data-driven patient access and therapy commercialization. Pharma Commerce will be one of the conference sponsors, alongside service providers including: Asembia, AssistRx, BRG, ConnectiveRx, EntityRisk, Phil, Redi.Health, and Turquoise Health. Details and registration for the event can be found here.
Key sessions of the conference include:
The Fight for the Dollar Keynote: Bill Roth, general manager and managing partner of Blue Fin Group and a Pharma Commerce columnist, will explore how chief commercial officers and access leaders can adjust to the significant financial pressures on all facets of drug commercialization to achieve a profitable lifecycle for the first three to five years.
The Pharmacy of the Future: Moderator Richard Prest, senior principal, Blue Fin Group, will explore the trends impacting the further evolution of the pharmacy model with industry experts: Thomas Cohn, chief strategy officer, Asembia; Jonathan Ogurchak, PharmD, co-founder and CEO, Zeal Specialty Pharmacy; and Harry Travis, president, The Travis Group.
Managing GTN in the New Models of the PBMs, Retailers and Distributors: Roth will moderate this panel exploring the pressures of new commercial models on net revenue optimization with esteemed panelists: Lance Wilkes, VP, senior equity analyst, Sanford C. Bernstein; Kent Rogers, venture partner, ARCH Venture Partners; and Albert Thigpen, operating advisor, Nautic Partners.
“Pharma manufacturers are facing regulatory and financial pressures like never before—all creating a massive impact on commercialization,” says IntegriChain CEO Josh Halpern. “Our conference uniquely examines current industry trends and delivers data-driven strategies and tactics for commercialization, contracting and reimbursement, net revenue forecasting, and channel management success in this new era.”
Understanding the FDA's Exemption for DSCSA Compliance
November 12th 2024In the quest for achieving full traceability, the exemption applies to certain trading partners under the Act, and postpones enforcement of final compliance requirements while acknowledging progress and ongoing challenges.
